NYSE:GMED

Globus Medical Stock Forecast, Price & News

$74.63
-0.03 (-0.04 %)
(As of 06/23/2021 12:56 PM ET)
Add
Compare
Today's Range
$74.43
$74.97
50-Day Range
$68.93
$74.66
52-Week Range
$43.22
$75.00
Volume2,686 shs
Average Volume455,010 shs
Market Capitalization$7.49 billion
P/E Ratio62.71
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.


Globus Medical logo

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products, comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue based products; and COALITION, COALITION MIS, COALITION AGX, MONUMENT, MAGNIFY-S, HEDRON IATM, HEDRON ICTM, INDEPENDENCE, INDEPENDENCE MIS, FORTIFY and XPAND families, SABLETM, RISE, RISE INTRALIF, RISE-L, ELSA, ELSA ATP, RASS, ALTERA, ARIEL, LATIS, CALIBER and CALIBER-L products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

436th out of 2,105 stocks

Surgical & Medical Instruments Industry

40th out of 174 stocks

Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Globus Medical (NYSE:GMED) Frequently Asked Questions

Is Globus Medical a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Globus Medical stock.
View analyst ratings for Globus Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Globus Medical?

Wall Street analysts have given Globus Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Globus Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Globus Medical
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings data on Tuesday, May, 4th. The medical device company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.12. The medical device company earned $227.34 million during the quarter, compared to the consensus estimate of $196.89 million. Globus Medical had a trailing twelve-month return on equity of 11.33% and a net margin of 14.73%. The firm's revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the firm posted $0.29 earnings per share.
View Globus Medical's earnings history
.

How has Globus Medical's stock been impacted by COVID-19?

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GMED stock has increased by 96.1% and is now trading at $74.63.
View which stocks have been most impacted by COVID-19
.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided EPS guidance of 1.890-1.890 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.840. The company issued revenue guidance of $925 million-$925 million, compared to the consensus revenue estimate of $881.64 million.

What price target have analysts set for GMED?

13 brokerages have issued 1-year price targets for Globus Medical's shares. Their forecasts range from $56.00 to $82.00. On average, they expect Globus Medical's share price to reach $73.43 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for Globus Medical
or view top-rated stocks among Wall Street analysts.

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 54, Pay $965.08k)
  • Mr. David M. Demski, CEO, Pres & Director (Age 63, Pay $1.48M)
  • Mr. Keith W. Pfeil, Sr. VP & CFO (Age 42, Pay $619.87k)
  • Ms. Kelly G. Huller Esq., Sr. VP & Gen. Counsel (Age 48, Pay $504.26k)
  • Mr. Daniel T. Scavilla, Exec. VP, Chief Commercial Officer & Pres of Trauma (Age 56, Pay $864.45k)
  • Mr. Brian J. Kearns, Sr. VP of Bus. Devel. & Investor Relations (Age 54)
  • Mr. A. Brett Murphy, Exec. VP of International Sales (Age 56)
  • Mr. Steven M. Payne, VP & Controller (Age 50)
  • Mr. Mike Reeder, Exec. Officer
  • Mr. Richard Holifield, Exec. Officer

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Globus Medical's key competitors?

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), The Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.58%), Janus Henderson Group PLC (6.44%), RTW Investments LP (1.67%), Champlain Investment Partners LLC (1.52%), GW&K Investment Management LLC (1.49%) and Geneva Capital Management LLC (1.28%). Company insiders that own Globus Medical stock include David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends for Globus Medical
.

Which major investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Standard Life Aberdeen plc, Point72 Asset Management L.P., Jupiter Asset Management Ltd., Marathon Asset Management LLP, Man Group plc, Barclays PLC, and Goldman Sachs Group Inc.. Company insiders that have sold Globus Medical company stock in the last year include David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, and Kelly Huller.
View insider buying and selling activity for Globus Medical
or view top insider-selling stocks.

Which major investors are buying Globus Medical stock?

GMED stock was purchased by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Polar Capital Holdings Plc, Geneva Capital Management LLC, Nuance Investments LLC, Millennium Management LLC, William Blair Investment Management LLC, BlackRock Inc., and Banque Pictet & Cie SA.
View insider buying and selling activity for Globus Medical
or or view top insider-buying stocks.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $74.63.

How much money does Globus Medical make?

Globus Medical has a market capitalization of $7.49 billion and generates $789.04 million in revenue each year. The medical device company earns $102.29 million in net income (profit) each year or $1.44 on an earnings per share basis.

How many employees does Globus Medical have?

Globus Medical employs 2,200 workers across the globe.

What is Globus Medical's official website?

The official website for Globus Medical is www.globusmedical.com.

Where are Globus Medical's headquarters?

Globus Medical is headquartered at 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.